- Home
- MIY vs AMRN Comparison
MIY vs AMRN Comparison
Compare MIY & AMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MIY | AMRN |
|---|---|---|
| Founded | N/A | 1989 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 334.3M | 287.9M |
| IPO Year | 1994 | 1998 |
Fundamental Metrics
Financial Performance| Metric | MIY | AMRN |
|---|---|---|
| Price | $11.89 | $11.60 |
| Analyst Decision | | Strong Sell |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $12.50 |
| AVG Volume (30 Days) | ★ 73.6K | 60.9K |
| Earning Date | 01-01-0001 | 10-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 55.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $181,104,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 39.22 |
| 52 Week Low | $11.01 | $11.25 |
| 52 Week High | $12.90 | $20.90 |
Technical Indicators
Market Signals| Indicator | MIY | AMRN |
|---|---|---|
| Relative Strength Index (RSI) | 57.46 | 29.91 |
| Support Level | $11.87 | N/A |
| Resistance Level | $12.44 | $14.50 |
| Average True Range (ATR) | 0.24 | 0.33 |
| MACD | 0.08 | 0.01 |
| Stochastic Oscillator | 100.00 | 31.34 |
Price Performance
Historical ComparisonAbout MIY Blackrock MuniYield Michigan Quality Fund Inc.
Blackrock Muniyield Michigan Quality Fund Inc is a closed end fund. Its investment objective is to provide shareholders with as high a level of current income exempt from U.S. federal income taxes and New York State and New York City personal income taxes as is consistent with its investment policies and prudent investment management.
About AMRN Amarin Corporation plc
Amarin Corp PLC is a pharmaceutical company. The company is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa. The company focuses on treatments to stop cardiovascular disease causing death, by providing patients, doctors and investors with reliable cardiovascular treatment options. Geographically, the company derives maximum revenue from United States.